On December 29, 2007, expert seminar of in-study KH902 stage I clinic program of Kanghong Pharmaceuticals Group was held in the Kanghong Science and Technology Building.

President of Kanghong Pharmaceuticals Group Ke Zunhong gave a warm reception to the participants of the meeting, and expressed heartfelt thanks to the great support provided by the experts to the Group. Meanwhile, he hoped to further strengthen the exchanges and the study with the experts, obtain the instructions from them in the aspects of product R & D and independent innovation. 

Commissioned by president Ke, General Manager of Kanghong Biological Technology Limited Dr. Yu Dechao made an introduction of the Group development situation, biotechnological innovation platform, in-study project development and the prospect to the experts. Dr. Zhang Ming of Sichuan University Huaxi Hospital ophthalmological center and Dr. Li Hong of Kanghong biotechnology pre-clinical research department pharmacological researcher respectively made special reports on KH902 stage I clinical trial program and pre-clinical studies. 

At the meeting, the experts have a full and lively discussion on KH902 stage I clinical program. Among the clinical program, the questions like selection/exclusion criteria, treatment program, quality control were discussed fully and deeply, and the agreement on implementation program was achieved.

Attendance included Ophthalmology Institute of Chinese Medical Association director and Eyeground Disease Team of Chinese Ophthalmology Institute leader Li Xiaoxin, Huaxi Hospital of Sichuan University ophthalmological professor Yan Mi, Eyeground Disease Team of Chinese Ophthalmology Institute assistant leaders Xu Xun, Tang Shibo, Zhang Junjun and other expert team members, Kanghong Pharmaceuticals Group vice president Zhao Xingping, Hao Xiaofeng and the leaders from related departments.